Ubs Asset Management Americas Inc Rubius Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.79 - $5.98 $24,154 - $182,838	-30,575 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$9.68 - $17.74 $16,678 - $30,566	-1,723 Reduced 5.33%	30,575 $295,000
Q3 2021 Nov 15, 2021	SELL	$17.6 - $25.91 $145,745 - $214,560	-8,281 Reduced 20.41%	32,298 $577,000
Q2 2021 Aug 16, 2021	BUY	$22.26 - $28.43 $349,014 - $445,753	15,679 Added 62.97%	40,579 $990,000
Q1 2021 May 14, 2021	BUY	$8.02 - $32.01 $103,458 - $412,929	12,900 Added 107.5%	24,900 $659,000
Q3 2020 Nov 13, 2020	SELL	$4.65 - $6.25 $43,235 - $58,112	-9,298 Reduced 43.66%	12,000 $60,000
Q2 2020 Aug 14, 2020	BUY	$4.01 - $6.88 $44,101 - $75,666	10,998 Added 106.78%	21,298 $127,000
Q2 2019 Aug 15, 2019	BUY	$13.5 - $19.94 $139,050 - $205,382	10,300 New	10,300 $0

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.